Article

Visual prognosis appears generally good after PPV for retained lens material

An analysis of visual outcomes in a contemporary series of cataract surgery eyes that underwent pars plana vitrectomy (PPV) for retained lens material indicates these complicated cases tend to do well, said Lawrence Y. Ho, MD.

An analysis of visual outcomes in a contemporary series of cataract surgery eyes that underwent parsplana vitrectomy (PPV) for retained lens material indicates these complicated cases tend to do well,said Lawrence Y. Ho, MD.

Dr. Ho reported the findings from a retrospective review that included analyses for predictors ofgood and poor visual outcomes. The series included 166 consecutive cases from a 6-year periodextending from January 2001 to January 2007. Follow-up exceeded 6 months in more than 80% of eyes.The visual results showed 72% of eyes achieved vision of 20/40 or better while only 10.8% ended upwith vision of 20/200 or worse.

"The outcomes in this series surpass those in prior large series that showed only 58% of patients hadvision of 20/40 or better while almost 18% saw 20/200 or worse. We believe improvements in both phacotechnology and vitrectomy combined with earlier detection of treatment complications, such as CMEwith more widespread use of OCT, may account for the difference. However, this warrants furtherinvestigation," said Dr. Ho.

Predictors of vision outcomes were examined in a multivariate analysis. Better presenting vision,insertion of a posterior chamber IOL, and absence of preoperative eye disease were associated with agood vision outcome.

Development of glaucoma and presence of preexisting eye disease were associated with a poor visionoutcome while anterior vitrectomy at the time of cataract surgery and sulcus lens placement atcataract surgery had protective value.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.